Dimensional Fund Advisors LP Acquires 103,237 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Dimensional Fund Advisors LP increased its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 16.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 717,188 shares of the company's stock after purchasing an additional 103,237 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.02% of ORIC Pharmaceuticals worth $5,788,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. XTX Topco Ltd grew its holdings in ORIC Pharmaceuticals by 120.9% during the 4th quarter. XTX Topco Ltd now owns 25,966 shares of the company's stock valued at $210,000 after buying an additional 14,209 shares in the last quarter. Barclays PLC boosted its position in shares of ORIC Pharmaceuticals by 6.9% during the fourth quarter. Barclays PLC now owns 114,692 shares of the company's stock worth $927,000 after acquiring an additional 7,431 shares during the last quarter. Invesco Ltd. grew its stake in ORIC Pharmaceuticals by 8.5% during the fourth quarter. Invesco Ltd. now owns 23,958 shares of the company's stock valued at $193,000 after acquiring an additional 1,876 shares in the last quarter. Wells Fargo & Company MN increased its holdings in ORIC Pharmaceuticals by 30.2% in the 4th quarter. Wells Fargo & Company MN now owns 35,857 shares of the company's stock valued at $289,000 after acquiring an additional 8,311 shares during the last quarter. Finally, ExodusPoint Capital Management LP bought a new stake in ORIC Pharmaceuticals in the 4th quarter valued at $189,000. Institutional investors own 95.05% of the company's stock.

ORIC Pharmaceuticals Price Performance

Shares of NASDAQ ORIC opened at $5.08 on Monday. ORIC Pharmaceuticals, Inc. has a 1-year low of $3.90 and a 1-year high of $14.67. The business's 50 day moving average is $5.90 and its two-hundred day moving average is $8.06. The stock has a market capitalization of $361.13 million, a P/E ratio of -2.79 and a beta of 1.37.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.09. As a group, equities research analysts anticipate that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on ORIC. HC Wainwright reissued a "buy" rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a report on Monday, May 5th. Cantor Fitzgerald reissued an "overweight" rating on shares of ORIC Pharmaceuticals in a research note on Tuesday, May 6th. JPMorgan Chase & Co. raised their price target on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Wedbush reaffirmed an "outperform" rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th. Finally, Oppenheimer decreased their price objective on ORIC Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $19.17.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.